LRAT (lecithin:retinol acyltransferase), an enzyme whose levels are modulated during malignant conversion, has been reported as the founder member of a new LRATlike family that includes tumor suppressors TIG-3 1-164 and Ha-Rev107 1-162 . The mechanisms that link these three proteins to carcinogenesis as well as the significance of a reported shared sequence homologous region remain unclear. This begs the question if the tumor suppressors possess enzyme properties and/or if the LRAT enzyme possesses tumor suppressor properties. We use the reported homologous region as a first approach to address the question from the perspective that all three proteins can possess tumor suppressor properties. We postulated that the homologous sequence harbors an antiproliferation domain within the full-length proteins and that dodecapeptides of this sequence possess antiproliferative activity. We report that H-TIG-3 111-123 , HHa-Rev107-1 111-123 and H-LRAT 160-171:C168L exhibited in vitro growth inhibitory activity in a human cutaneous melanoma (HCM) model and affected tumor growth in a nude mouse model. Further, in peptide-sensitive HCM cells, these peptides crossed the plasma membrane and localized to the nucleus, where they could bind and activate promoters of transcription factors involved in G1!S transition. Moreover, peptide-induced abrogation of cyclin dependent kinase-2 expression was concomitant with subcellular re-distribution of cyclins E and A. Indeed, the sequence homologous region within each full-length wildtype protein as well as the growth inhibitory peptides can form alpha helices, a likely configuration for binding to DNA. This is the first report that this sequence homologous region ) within these LRAT-like proteins harbors an anti-proliferative domain with DNA binding properties. Sequences from this sequence homologous region can be used as templates for anti-tumor drug design and as probes to investigate disease-related mechanisms and structure-activity relationships of the full-length proteins, TIG-3 1-164 , Ha-Rev107 1-162 and LRAT [160][161][162][163][164][165][166][167][168][169][170][171] .
Introduction
Tumor suppressors and transferases have been linked to carcinogenesis, and studies that investigate the relevance of this link have led to elucidating mechanisms of the disease process and to facilitating development of treatments. In fact, dualfunctionality of proteins as relates to cell growth and carcinogenesis has been demonstrated for several enzymes; for example, P-TEN, an enzyme with phosphatase activity and glycosyltransferases, EXT1 and EXT2, have been shown to possess both enzyme and tumor suppressor properties (1, 2) . Furthermore, design and synthesis of peptides from their fulllength proteins to yield therapeutic agents has proven successful. For example, peptides derived from laminin displayed cell growth modulating activity (3) . Rational designed peptides have been shown to interrupt de-regulated Ras signaling (4); synthetic peptides have been shown to selectively target cancer cells (5) and to be used for vaccine development (6) .
Lecithin:retinol acyltransferase (LRAT), classified as an enzyme that esterifies retinol through transfer of an acyl group from lecithin, shares no sequence homology with other known acyltransferases (7) . However, LRAT recently has been shown to have its phylogenetic origins in a diverse family of proteins (8) , and it is this diversity that underlies our question of possible LRAT function in addition to its enzymatic activity. In fact in the NIpC/P60 superfamily of enzymes, LRATlike family members are classified by a circular permutation and a conserved cysteine (8) . In this regard, among the members of the LRAT family are the two Class II tumor suppressors, human tazarotene induced gene-3 (H-TIG-3 ) and human Harvey ras revertant 107-1(H-Ha-Rev107-1 ) (9, 10) . These tumor suppressors have a 27 and 25% sequence identity to LRAT, respectively, and all family members share a region 12 amino acids long of very high sequence homology (Table I) . Further, LRAT, Ha-Rev107 and H-TIG3 genes are retinoid responsive, thus linking these proteins to the retinoid specific receptors, RAR-a, -b, -g, through which the retinoids mediate their effects (11) . Relevant to our study those studies that demonstrated reduced LRAT enzyme activity and/or expression associated with different types of cancer, such as prostate, renal and breast (12) (13) (14) . In human skin, the LRAT enzyme is functional in the basal cell layer where it catalyzes retinyl ester synthesis (15) . Studies from our lab indicate that, in vitro, normal human proliferating melanocytes express the LRAT protein and are capable of retinol esterification by this enzyme (16) . In addition, the Class II tumor suppressors, HHa-Rev107 and TIG, are frequently downregulated in tumorigenic cell lines and psoriasis, basal carcinomas and some aggressive squamous cell carcinomas (17) . This protein/geneassociated aberrant activity of the LRAT enzyme and these two tumor suppressors in carcinogenesis, the reports in the literature of the dual functionality of enzymes, the fact that these three proteins are retinoid responsive and the recent report of these three proteins as members of the same family of proteins, combined with the reports of the shared 12-amino acid sequence homology of these tumor suppressors with LRAT (7, 9) , prompted us to ask if this sequence might be an anti-proliferation domain and if wild-type dodecapeptides synthesized from this homologous region would possess growth-inhibitory properties. If so, the sequence homologous region could provide a clue to the relevance of the LRAT-associated aberrant behavior in cancer.
Cell cycle, particularly control of G0/G1!S, is intimately associated with carcinogenesis and the retinoids and their receptors, through modulation of retinoid responsive genes, are critical regulators of cell growth and differentiation. For instance, retinoic acid receptor-beta (RAR-b), which is downregulated in some cancers, has been shown to modulate expression of the retinoid responsive cyclin E (18) . The G1 cyclins, E and A, have as their cognate kinase, cyclindependent kinase 2 (cdk2). Expression levels as well as activity of these complexes are known to be responsible for checkpoint control, the so-called R-point, as the cell transits through to the S-phase. Indeed, it is the R-point that is said to play a critical role in inhibiting malignant transformation (19) . Numerous transcription factors interact in coupling the G1/S machinery to the initiation of DNA replication. However, the transcriptional link between the cyclins and DNA synthesis/ replication is the E2F family of transcription factors. This family is necessary for the formation of pre-replication complexes, requires interaction with cdk2 products, and interestingly has been shown to have a role in G1/S progression similar to that of Myc (20) .
Human melanoma is one of the models of choice to investigate tumor progression toward metastasis (21) . Use of this model also permits one to investigate approaches that may be clinically useful in cutaneous melanoma, which accounts for 477% of all deaths from skin cancer in the USA (22) and is the fastest rising cancer in developing countries (23) . Studies from our lab have shown that melanocyte transformation results in two morphological phenotypes, which express LRAT protein but possess divergent esterification properties. Thus, in sharp contrast to other LRAT-associated cancers, epithelioid melanoma cells esterify retinol but fibroblastoid melanoma cells do not (16) . In a continued effort to elucidate the significance of the associated aberrant expression/activity of LRAT in carcinogenesis, we used a human cutaneous melanoma model to ask whether the sequence homologous region found in the wild-type full-length proteins H-LRAT 160-171 , H-TIG-3 , and H-Ha-Rev107-1 1-162 functions as an anti-proliferative domain, and if dodecapeptides of these sequences can function as growth inhibitors.
Materials and methods
Peptide synthesis and fluorescein modification All peptides were synthesized by SIGMA-GENOSYS (Woodlands, Texas). On receipt, lyophilized peptides were solubilized in sterile ultra pure water (KD Medical, Columbia, MD) to achieve a 10 mM stock, aliquoted and stored at À80 C or immediately used. Peptides H-LRAT 160-171 , H-Ha-Rev107-1 112-123 and H-TIG-3 112-123 were designed based on the published 12-amino acid sequence homology of their respective full-length wild-type proteins (9) . An additional N-terminus amino acid, from the published full-length sequences of H-Ha-Rev107-1 or H-TIG-3 , was added to the N-terminal sequences to facilitate purification. Thus, amino acid 111 E or R was added, respectively (Table I) . Placement of the fluorescein-label and fluorescein labeling of peptides were determined based both on structural bioinformatics and fluorescein label chemistry (24) . Flc denotes the fluorescein label placed at the N-terminus of the peptide (flc-NCEHFVTYLRYG ¼ fluorescein labeled H-LRAT 160-171:C168L ; flc-RNCEHFVAQLRYG ¼ fluorescein labeled H-TIG-3 111-123 ). Unrelated peptide (GYFHEGFHGYFGY) was designed based on amino acids in the dodecapeptide that were not part of the tri-peptide sequence (AQL, AQC, NEL, TYL) distinct to each peptide. Active H-LRAT (H-LRAT 160-171:C168L ) and inactive H-TIG3 (H-TIG3 111-123:L120C ) peptides were designed based on the rationale that follows. Rational design H-LRAT 160-171:C168L LRAT enzyme and the two tumor suppressor proteins share their highest degree of sequence homology within a 12-amino acid region/dodecapeptide. Within this region are four features on which we focused: a tri-peptide sequence unique to each 12-amino acid region, a leucine residue common to the tumor suppressors within their unique tri-peptide sequences, a cysteine residue in the LRAT dodecapeptide at the same position as the leucine residue in the tumor suppressor dodecapeptide and a C-terminal tri-peptide that is MKNPMLEVVSLLLEKLLLISNFTLFSSGAAGEDKGRNSKYETSSFHRGDVL  51  H-LRAT  MRAPIPE  7  H-HA-REV107-1  MASPHQE  7  H-TIG-3  EVPRTHLTHYGIYLGDNRVAHMMPDILLALTDDMGRTQKVVSNKRLILG  100  H-LRAT  PKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSALT  56  H-HA-REV107-1  PKPGDLIEIFRLGYEHWALYIGDGYVIHLAPPSEYPGAGSSSVFSVLSN  56  H-TIG-3  VIVKVASIRVDTVEDFAYGANILVNHLDESLQKKALLNEEVARRAEKLLG  150  H-LRAT  DKAIVKKELLYDVAGSDKYQVNNKHDDKYSPLPCSKIIQRAEELVGQ  103  H-HA-REV107-1  SAEVKRERLEDVVGGCCYRVNNSLDHEYQPRPVEVIISSAKEMVGQK  103  H-TIG-3  1 2 3 4 5 6 7 8 9 101112  FTPYSLLWN NCE HFV TY C R Y G TPISPQSDKFCETVKIIIRDQRSVLASAV  200  H-LRAT  EVLYKLTSE NCE HFV NE L R Y G VARSDQVRDVIIAASVAGMGLAAMSL  150  H-HA-REV107- 
Boxed area, published 12-amino acid sequence homology shared among the three wild-type full-length proteins. Arabic numerals above the boxed area indicate sequential re-numbering of each individual amino acid residue within the dodecapeptides, independent of the respective sequence number. Underscored amino acids, R, Y, G amino acids common to all three anti-proliferation peptides and found in RAR and RXR at points of contact with RARE.
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juxtaposed to the unique tri-peptides and is common to each 12-amino acid region (Table I ). We predicted that (i) the 12-amino acid sequence of the full-length tumor suppressors harbors a domain that lends tumor suppressor properties to these peptides, (ii) leucine is important to the postulated anti-proliferative activity because both dodecapeptides of the full-length tumor suppressors contain a leucine (L120) at Position 9, which is within the tri-peptide sequence distinct to each peptide, (iii) H-LRAT 160-171 would be inactive as an anti-tumor agent because at Position 9 wild-type H-LRAT 160-171 contains a cysteine (C168), one of the two cysteines shown to be important although not essential to optimal enzyme activity of the full-length protein (7), while a cysteine to leucine (C168L) mutation would yield an active HLRAT:C168L growth-inhibitory agent and that (iv) if the former were true then a mutation in L120 (L120C) of H-TIG-3 111-123 or H-Ha-Rev107-1 111-123 peptide would result in an inactive anti-proliferative peptide ( Figure 1 ). Chemical structures were generated, checked and cleaned-up in ChemDraw 6.0 (CambridgeSoft Cambridge, MA). (Table I) . N-terminal amino acids in bold italics added to facilitate synthesis. Underscored sequences are the three amino acids that distinguish each of the three peptides. Highlighted chemistry reflects the underscored three-amino acid sequences. Arrows indicate the position of the residues that are predicted to be important in anti-proliferation activity (L120) or known to be important in LRAT Human tumor xenograft mouse model E:WM-115 sub-confluent monolayers were harvested and resuspended in phosphate-buffered saline (PBS) just before use. A total of 20, six-week-old, Balb/c nu/nu female mice were weighed and inoculated subcutaneously in the right flank with 0.1 ml PBS or 5 Â 10 6 cells in 0.1 ml PBS. Mice were grouped as 5 mice for mock-treated, 15 mice for growth inhibitory peptide (GIP) treatment which was subdivided into 5 mice/GIP. Naive animals were maintained to check for spontaneous tumor formation. Tumor volume was determined according to the formula: [(w)2 (l)]/2 (25), and tumor count was based on the observed development of one tumor/mouse. Tumors were allowed to reach a size that would permit evaluation of changes in tumor size. To assess peptide efficacy as an anti-tumor agent, a 0.05 ml GIP solution was administered as a single treatment, three-site intra-tumoral injection of 0.05 mg/kg body wt. Three single treatments were given over a 10-day time period. Animals were weighed weekly and tumor size measured by calipers on the day of treatment (Day 1) and every other day after treatment. At the end of the treatment protocol, two animals with excessive size tumors were treated daily, over a 4-day period, with H-Ha-Rev107-1 111-123 .
Cell culture

Western analysis
At each specific time point, peptide-treated and vehicle-treated monolayers were lysed with SDS lysis buffer. 20 mg of protein were loaded on a 4-12% Bis-Tris SDS-PAGE (Novex, Invitrogen, Carlsbad, CA) reducing gel, separated by electrophoresis, and transferred onto a 0.2 (m polyvinyldiene difluoride membrane. Blots were probed with polyclonal rabbit anti-actin (Chemicon International, Temecula, CA) and antibodies to HMGI(Y)/HMG A1, cyclin A, cyclin E, cdk2 and RARb 1/2 (Santa Cruz Biotechnology, Santa Cruz, CA). Antibody specificity was verified using Santa Cruz control cell extracts and molecular weight standards. Specific signal was quantified by ImageQuant Analysis (Molecular Dynamics, Sunnyvale, CA). All experiments were performed in triplicate for a minimum of two times.
Subcellular localization
Subcellular localization of peptides was assessed using fluorescein labeled H-TIG-3 111-123 (flc-RNCEHFVAQLRYG) or H-LRAT 160-171:C168L (flc-NCEHFVTYLRYG) and real time confocal laser scanning fluorescence microscopy. Peptide localization was studied at peptide concentrations used in cell proliferation methods. Briefly, the most GIP-sensitive melanoma cells (E:WM115), the least GIP-sensitive melanoma cells (F:Hs688(B)T and the GIP-insensitive normal melanocytes (HFSC/2) were seeded, in triplicate, in 0.17 mm delta T dishes (Bioptechs, Butler, Pennsylvania ) and grown to 60-70% confluence. The cultures were placed on the 37 C temperature controlled stage, treated with vehicle, flc-H-TIG-3 111-123 or flc-H-LRAT 160-171:C168L , and images were continuously captured over 48 h. Additional images were captured at 72 and 96 h. During the last 30 min of the peptide treatment timecourse, peptide-treated cells were incubated with the nuclear staining agent, Hoechst 33342 (Molecular Probes, Eugene, OR). Confocal fluorescent images were collected with a Bio-Rad MRC 1024 confocal scan head mounted on a Nikon Optiphot microscope with a 60Â planapochromat lens then saved using Bio-Rad LaserSharp software. Experiments were performed in excess of three times. Line graph intensity profiles of fluorescence intensities were measured after acquisition with the Zeiss AIM software.
Transcription factor analysis
Transcription factor gene array analysis (Panomics Transcription factor pathfinder array TranSignal kit, Redwood City, CA) was used to profile activities of 54 transcription factors involved in signal transduction. Briefly, nuclear extracts were prepared using the Pierce nuclear extraction kit (Rockford, IL) from 72-h peptide and vehicle treated cultures and processed according to the manufacturer's instructions. Differential hybridization signals, corresponding to differentially bound transcription factors by the nuclear extracts, were captured by West Pico Chemiluminescence Imaging (Pierce Rockford, IL) and quantified in ImageJ. Specificity of GIPs binding was determined by titrating the peptide (32 ng/blot and 32 pg/blot) against the transcription factor labeled blots and using the optimal GIP concentration (32 ng) for a final specificity test of GIP (32 ng) versus scrambled peptide (32 ng) on each blot. Optimal GIP concentration was based on signal to noise ratios at each dilution. Values 41.5-fold above background were considered positive and 'boxed' as a binding signal. Experiments were performed a minimum of two times. Electrphoretic mobility shift assay Panomics electrphoretic mobility shift assay (EMSA) kit (Redwood City, CA) was used to verify select GIP-bound transcription factors. Briefly, vehicletreated or GIP-treated nuclear extracts were incubated with the specific double-stranded biotinylated probe, that is DNA response elements [RXRE(DR1): AGGTCACAGGTCACAGGTCACAGGTCACAGGTCA or RARE(DR5):AGGTCACCAGGAGGTCACCAGGAGGTCACCAGGAGG-TCACCAGGAGGTCA]. Each sample was separated on 6% native polyacrylamide gels and shifted bands that corresponded to protein/DNA complexes were captured by an HRP-based detection system. Experiments were performed in excess of three times. Transcription factor cell reporter assay The TranSignal Transcription Reporter Array kit (Panomics, Redwood, CA) was used to assess GIP-induced transcription factor activation of select GIPbound transcription factors [EGR, E2F, NFAT, RARE (DR5), RXRE (DR1), TR (DR4), VDR (DR3)]. Briefly, 80-90% confluent E:WM-115 cells were transfected with the plasmid DNA mix then treated with vehicle (water), H-TIG-3 111-123 or H-LRAT 160-171:C168L . Specific signal was determined using a horseradish peroxidase chemiluminescence detection system and quantified using IMAGEJ. Arbitrary galactosidase units were determined by normalization against empty vector. Data are presented as the mean of two independent experiments with four replicates/construct/experiment.
Molecular models
The full-length sequences of the H-LRAT 1-230 , H-TIG-3 1-164 and H-HaRev107 1-162 proteins were submitted to 12 computer programs for protein secondary structure prediction. The programs used and their references are listed in Table II . In each case we submitted the individual sequence of each protein; however, many of the methods include an automatic sequence search to find and align homologous sequences to the query before making the prediction. Helical models for each peptide were generated using the Maestro interface for MacroModel (Schrödinger) and subjected to a small 500-step conjugate gradient minimization using the OPLS-AA forcefield (27) with continuum solvent (28) .
Transient transfection of RAR-b PCMX-hRAR-b 2 was a generous gift of Ronald M. Evans, Gene Expression Lab (San Diego, CA). Plasmid was grown and purified according to Qiagen Endofree Plasmid protocol [Briefly, E:WM-115 cells were transfected with RAR-b 2 -plasmid using Super-Fect (Qiagen, Valencia, CA)] Super-Fect alone, vehicle for 4 h at 37 C in 2% serum containing medium. Transfection solutions were removed and cells were maintained 48 h in 10% medium with and without 10 À6 M 9-cis retinoic acid. Cells were viewed daily for morphological changes, harvested and processed as described in methods for cell proliferation. After conditions were established experiments were performed a minimum of two times.
Statistical analysis
The t-Test for the significance of the difference between the means of two independent samples was used to evaluate the effect of GIPs on normal human epidermal melanocytes. All P-values were two-sided and were considered statistically significant if P 5 0.05. Standard deviations were calculated using Excel software program.
Results
In vitro proliferation studies: proof of hypothesis H-TIG-3 111- 123 1, H-Ha-Rev107-1 111-123 2, and LRAT 160-171:C168L 4 peptides inhibited proliferation of human melanoma cells, E:Hs939.T (not shown) and E:WM-115, [mean(%) AE SD] 60.9 AE 8.9, 42 AE 5.5 and 39.2% AE 2.8, respectively when used at 1 mM/day, over 48 h (Figure 2A ) but the homologous wild-type H-LRAT 160-171 dodecapeptide 3 did not (4.6% AE 1.7). Thus, the C168L mutation in the LRAT dodecapeptide resulted in a 9-fold increase in growth inhibition relative to the wild-type H-LRAT 160-171 3. In sharp contrast, the L120C mutation in H-TIG-3 111-123 resulted in an inactive peptide (2% AE 1.4) (Figure 2A) , so that the growth inhibitory activity exhibited by the wild-type H-TIG-3 111-123 peptide was decreased 30-fold, thus validating the significance of the leucine residue in growth inhibitory activity.
Importantly, we observed that the anti-proliferative peptides were inactive in normal melanocytes. Evaluation of 24-and 48-h peptide-treated versus untreated HFSC/2 normal melanocytes did not show a significant change in doubling time of the cells (P 5 0.05) ( Figure 2B ). Neither trypan blue staining nor Annexin V/propidium iodide FACS analyses showed evidence of cell death or changes in cell morphology in normal melanocytes 496 h or these anti-proliferative peptide treated melanoma cells within 72 h (data not shown).
GIP inhibit proliferation in cells lines derived from different stages of melanomagenesis
Proteins can be classified as tumor suppressors based on different properties, including structure, sequence, biological activity and function. The observed peptide growth inhibitory activity of H-Ha-Rev107-1 111-123 , H-TIG-3 111-123 and H-LRAT 160-171:C168L satisfies a criterion for tumor suppressor List of secondary structure prediction methods used to arrive at a consensus for secondary peptide structure, with the corresponding references. Using multiple prediction methods has been shown to yield much greater predictive accurarcy (26) . LRAT-like proteins possesses anti-proliferative activity activity. Because H-TIG-3 111-123 was the most effective of the three GIPs, it was used as the prototype to evaluate the ability of the GIPs to inhibit cell proliferation in cell lines representative of progression in melanomagenesis. 1 mM /day, over 48 h, of H-TIG3 111-123 significantly inhibited proliferation of cells from the primary site tumor cell lines established from two different patients (E:WM-115 ¼ 60% and F:Hs.688(A).T ¼ 55%). The observed levels of inhibition of cell proliferation (Figures 2A and 3,) without evidence of apoptosis are equivalent to those reported in the literature for 0.1 ng/ml of transforming growth factor beta-1 (TGFb-1) in neuroendocrine tumor cells (29) . Even though the H-TIG-3 111-123 was less effective in cells from the metastatic matches, cells from the metastasized epithelioid tumor, E:WM-266-4 at 33%, were more sensitive to H-TIG-3 111-123 than those of the metastasized fibroblastoid tumor, F:Hs.688(B).T at 8.3% (Figure 3) . Hence, the epithelioid melanoma cell line is more responsive to GIP than the fibroblastoid phenotype; furthermore, cell lines from primary sites tumors are more sensitive to GIP than their metastatic matches, regardless of morphological phenotype.
Human xenograft nude mouse model indicates that GIPs affect in vivo growth
The in vitro anti-proliferation activity of the GIPs prompted us to ask whether these peptides inhibit tumor growth. Subcutaneous human xenografts of the peptide sensitive E:WM-115 cells in Balb/c nu/nu female mice were used to assess in vivo growth inhibitory properties of the GIPs. One palpable tumor mass/mouse (n ¼ 16) appeared at the grafting site within 1-3 months (Table III) that increased in size !þ3.4 at the end of the protocol were considered non-responsive to GIP. In the GIP-treated tumors (n ¼ 11), responsive GIP-treated tumors (n ¼ 9) were 3.1-4.5-fold smaller. In 5 of 11 tumors (nos 6, 7, 11, 12 and 16), the actual size of the tumor was reduced while tumor size was contained for 4 of 11 tumors (nos 8, 13, 17 and 18). Two of the GIP-treated tumors (nos 9 and 14) were resistant to GIP treatment. Growth inhibitory effects lasted 12 days after the final treatment, at which time tumor cell growth increased up to 4-fold (data not shown). To test the observed cytostatic effect (nos 8, 13 and 17) of GIPs, mice with the largest tumors (4500 mm 3 ), one from the H-TIG-3 111-123 treatment group (no. 9) and one from the PBS-treatment-group (no. 5), were treated with daily intra-tumoral injection over 4 days with 0.15 mg/kg body wt/0.05 ml/tumor H-Ha-Rev107-1 111-123 . As a result tumor growth was blocked, and this block was lifted within 7 days after the last intra-tumoral injection (data not shown). These in vivo data suggest that the GIPs possibly behave as anti-neoplastic agents; however, a larger study would need to be conducted to validate this. We next attempt to elucidate the mechanism of the action of the GIPs by investigating their (i) cellular and molecular interactions, (ii) intracellular localization and (iii) structure.
GIPs' effect on G1!S cell cycle proteins Because all three GIPs possessed growth inhibitory activity in melanoma cells, we studied the effect of the GIPs on candidate proteins common to both carcinogenesis and cell cycle molecular pathways. It is known that the retinoids, their receptors and specific retinoid responsive genes, such as LRAT, are part of a regulatory feed-back loop. Further, since the wild-type full-length protein H-TIG-3 1-164 is induced by the RAR-b/g selective ligand, tazarotene, both H-TIG-3 1-164 and H-LRAT 1-230 being retinoid responsive, and RAR-b has been shown to be downregulated in some cancers, we hypothesized that RAR-b would be a GIP molecular target in peptide sensitive tumor cells. RAR-b basal expression levels were $3-fold less in epithelioid melanoma cells, E:Hs939.T, relative to normal proliferating melanocytes (HFSC/2). Incubation with GIPs induced upregulation of RAR-b protein in these melanoma cells to levels observed in normal proliferating melanocytes. A similar phenomenon was observed for the chromatin remodeling protein/transcription factor HMG A1, a high mobility group protein, specifically expressed in skin and frequently associated with neoplastic transformation/ metastasis ( Figure 4A ). HMG A1 contains retinoic acid receptor elements (RAREs) in its promoter and is known to interact Figure 4B . Outer shell, cytoplasm; inner shell, nucleus; A and E, cyclin A and cyclin E, respectively; E lmw, cyclin E lower molecular weight products; cdk2, cyclin dependent kinase 2. This drawing does not reflect the expression levels of these proteins.
LRAT-like proteins possesses anti-proliferative activity
with transcription factors nuclear factor kappa-B (NFk-B), RAR and nuclear factor of activated T cells (NFAT) (30) .
We then assessed the expression levels and cellular distribution of cyclin E, a cell cycle regulator that is modulated by RAR-b and, like RAR-b, contains an RARE (DR5) and is important in G1!S (31,32). Moreover, cyclin E-cdk2 complexes found in the nucleus of normal cells are essential for timely entry into S-phase in some cell types (19) . Cyclins E D.P. Simmons et al. and A were found to partition in the nucleus of normal melanocytes, with cdk2 found in both nuclear and cytoplasmic fractions ( Figure 4B ). Melanoma cells, on the other hand, showed partitioning of cyclins E and A into both cytoplasmic and nuclear fractions with restriction of cdk2 to the cytoplasmic fraction. GIPs were effective in re-partitioning of cyclin A into the nucleus in melanoma cells, and incubation with H-LRAT 160-171:C168L resulted in re-distribution of cyclin E to the nuclear compartment. Curiously, H-TIG-3 111-123 -treated melanoma cells showed both cytoplasmic and nuclear distribution and induced appearance of a lower molecular weight (LMW) form of the cyclin E in the nucleus. It has been reported that only tumor cells have the machinery, including the protease calpain, to process cyclin E into these LMW forms (33) . Hence H-TIG-3 111-123 possibly induces upregulation/ expression of calpain.
The observed GIP-induced cyclin re-distribution can play a role in achieving a 'normal' cell cycle profile, but cyclin protein expression is also critical. After normalization against actin, we found that total cyclin E levels were elevated 15-fold in the vehicle-treated E:WM-115 melanoma cells relative to the normal melanocytes and this increased expression was reduced, albeit to a small extent by GIP treatment. Total cyclin A was over-expressed as well in the E:WM-115 melanoma cells relative to normal melanocytes, and this expression also was slightly downregulated by H-TIG-3 111-123 and unaffected by H-LRAT 160-171:C168L . Interestingly, in these same melanoma cells, total cdk2 expression was abrogated by LRAT 160-171:C168L and significantly downregulated by H-TIG-3 111-123 with detectable amounts in both nuclear and cytoplasmic fractions ( Figure 4B ). Figure 4C depicts a summary of the distribution of these important G1!S cell cycle proteins.
GIPs move to the nucleus in peptide sensitive melanoma cells Modulation of transcription factors RAR-b and HMGA1, of the G1 cyclins A and E, of cdk2, as well as the observed differences in sensitivity of the matched tumor pairs to the GIPs compelled us to investigate the subcellular localization of these GIPs. Fluorescein-labeled H-TIG-3 111-123 or H-LRAT 160-171:C168L combined with laser imaging confocal microscopy were used to assess the ability of the GIPs to cross the cell membranes of GIP-sensitive and insensitive cells. Sensitivity was based on proliferation data (Figure 3) . Time course experiments with these fluorescein-labeled peptides showed that, within 48 h, at all concentrations, both H-LRAT 160-171:C168L and H-TIG-3 111-123 ( Figure 5A ) crossed the plasma and nuclear membranes and localized to the nucleus of the GIP-sensitive primary site epithelioid melanoma cells, E:WM-115. However, in the less sensitive fibroblastoid metastatic cells, F:Hs.688(B).T, H-LRAT 160-171:C168L ( Figure 5B.1 and B. 2) or H-TIG-3 111-123 ( Figure 5B.3) localization was restricted to the cytoplasm. In sharp contrast, the normal proliferating melanocyte [field shown in both phase contrast (left panel) and fluorescence] fluorescein labeled GIP was not found in the cell ( Figure 5C ). Both the scrambled peptide and the inactive wild-type LRAT peptide were able to cross the plasma/nuclear membranes in peptide sensitive cells, but in the case of the former distribution was throughout the cell (data not shown). Line graph intensity profiling of the tumor cells captured in Figure 5A and C clearly demonstrates peptide nuclear localization in epithelioid tumor cells versus cytoplasmic localization in fibroblastoid tumor cells ( Figure 5D ). The observed cellular distributions were the same at each time point captured.
GIPs bind to and GIP-treated nuclear extracts interact with transcription factor cis-binding elements of proteins involved in G1!S GIP localization to the nucleus ( Figure 5 ) and modulation of transcription factors, RAR-b and HMG A1 (Figure 4) , led us to speculate that the GIPs may affect growth by interacting with transcription complexes, either by binding directly to DNA or by interacting with protein-DNA complexes. Indeed, these GIPs may well be involved in DNA binding since they are basic peptides and basic peptides have been shown to enhance protein-DNA interactions (34) . We used a 'pathfinder' DNA transcription array and cell fractionation of H-TIG-3 111-123 -treated E:WM-115 melanoma cells to address these questions. Figure 6A ). In fact, in a cell-free assay used to assess direct peptide binding to DNA, GIPs directly bound AP2, MEF-1, OCT-1, Pax-5, SMAD 3/4 and a unique subset Myc-max ( Figure 6B ). The scrambled peptide control, used at the same concentration as the GIP (See Materials and methods), did not bind any of these elements. A concept map of the bound transcription factors from the different treatment groups revealed their common and unique subset of transcription factor cis-acting elements ( Figure 6C ).
We performed an EMSA to confirm the nuclear extract array data. Because GIPs were capable of upregulating RAR-b protein expression ( Figure 4A ), which requires heterodimers of RAR and RXR, we were especially interested in the interaction of nuclear extracts from H-TIG-3 111-123 -treated E:WM-115 cells with RARE(DR5) and RXRE(DR1). Three different specific migrating binding complexes were found as determined LRAT-like proteins possesses anti-proliferative activity by 100Â competitor probes. In nuclear extracts from both the vehicle-treated and GIP-treated E:WM-115 cells, RAR-E(DR5) biotinylated probes specifically bound the slowest migrating complex, S1. However, in H-LRAT 160-171:C168L -treated nuclear extract substantially more S1 complex was found than in vehicle-treated. There are only marginal differences in amount of S2 complex found across the three treatment groups, whereas, the fastest migrating complex, S3, is found in H-TIG-3 111-123 -treated extracts ( Figure 7A ). RXRE(DR1) binding pattern shows that a specific, S1, is uniquely found in nuclear extract from H-LRAT 160-171:C168L -treated E:WM-115. S3, is found in nuclear extracts from H-TIG-3 111-123 -treated E:WM-115, while an S2 is common to all three treatment groups. In fact, we believe this RARE EMSA data can serve as a paradigm for what we propose could be a GIP-recruitment of different proteins to the transcription complex. Indeed, when similar RAR-b EMSA binding profiles were reported in the literature, it was suggested that the different migrating complexes for RARE beta were due to sequentially occupied RXR homo-dimers and RAR-RXR hetero-dimers (35) . Moreover, RXR can heterodimerize with VDR and TR. Our array concept map, which revealed unique and overlapping subsets of GIP alone compared to nuclear extracts from GIP-treated and vehicle-treated tumor cells, corroborates this. The order of binding, the response elements bound, and subsequent transcription are most likely dependent upon the protein milieu in the microenvironment, reminiscent of co-activator/co-repressors recruitment and interaction with response elements to modulate transcription through chromatin remodeling (36, 37) . Additional transcription factor response elements (AP2, Myc, Oct-1 and SMAD 3/4) were tested by EMSA and shown to validate their respective binding array results (data not shown). by the GIP-treated nuclear extract, clearly is not inducible ( Figure 7C ). This may be a function of the cells' competition for RXR, which is the binding partner for vitamin D receptor 3 (VDR3), throid hormone receptor (TR) and RAR, the absence of the necessary co-activators to activate and/or the presence of co-repressors to inhibit VDR3 transcription.
GIPs are predicted to form alpha helices We next addressed whether these peptides formed biologically relevant secondary structures. The three-dimensional structures of the full-length H-LRAT , H-TIG-3 and HHa-Rev107 proteins are difficult to predict, since they have no detectable homology to any other protein of known structure. As a first step toward understanding the structurefunction relationship of the proteins and importantly their homologous dodecapeptide regions, we performed a series of computational secondary structure predictions on each sequence. These predictions indicated that the dodecapeptide region of each full-length protein sequence is a discrete secondary structural element because it is flanked on each side by regions of random coil (data not shown). Modeling predictions also suggested that the secondary structural element is likely to be an alpha helix ( Figure 8A ). This helix formation is of considerable interest since alpha helices are well-documented DNA binding structures (38) and it is this alpha helix configuration that we believe permits the GIPs to engage in the observed binding of DNA response elements. However, it is not clear from our models what significance the key leucine residue holds. We speculate that the helix residues potentially important in DNA contacts are within the terminal RYG (AA 169-171 /H-LRAT 160-171:C168L and AA 121-123 /H-TIG-3 and H-Ha-Rev107-1) and the adjacent tri-peptide unique to each GIP[AQL 118-120 (H-Ha-Rev), NEL 118-120 (H-TIG3), TYL 166-168 (H-LRAT)] ( Figure 8B ). This speculation is loosely based on a three amino acid sequence, NYL, found in zinc fingers in the region between the fingers, proximal to the D-box second zinc finger, within 'M4' (39) . Interestingly, the single R residue in the 'M5' region, between the zinc fingers distal to the P-box of zinc finger 1, is shown to be a very important DNA contact in the nuclear receptor family. 
Furthermore, the C-terminal RYG amino acid sequence common to the GIPs is found in RXR and RAR DNA binding domains and has been shown by NMR, molecular modeling and crystallography to have points of contact with the DNA phosphates of RARE, such that 8 of 15 amino acids in RAR and 9 of 15 amino acids in RXR are R, Y, G, with a random spatial distribution (R-X n -Y-X n -G) (40) .
DISCUSSION
LRAT has been reported as the founder member of a new class of enzymes (41) that includes proteins as diverse as tumor suppressors, including Ha-Rev107 and H-TIG-3, named LRAT-like proteins (8) . We tested whether a sequence homologous region shared among these three proteins could have importance in understanding the mechanisms of their link to carcinogenesis and possibly implicate a shared function. We have used a human cutaneous melanoma model to demonstrate that the sequence homologous region can behave as a growth regulatory domain with DNA binding properties and that peptides of these sequences can be used to develop potential anti-tumor molecules as well as to investigate structureactivity relationships of full-length of H-LRAT, H-TIG-3 and H-Ha-Rev107. Most interesting is our observation that peptide sensitivity relates to morhphological phenotype and disease progression of the melanoma cell, that is, epithelioid versus fibroblastoid and primary tumor cell versus metastatic. Because we observed that one aspect of peptide-sensitivity in these two morphological phenoytypes was correlation with the ability of the peptide to cross the plasma and nuclear membrane, we believe it is worth investigating whether this difference in behavior of the peptides (or response of the cells to the peptides) in the two morphological phenotypes may reflect membrane differences in the two morphological phenotypes, for example, redox potential and/or the presence/absence of shuttle proteins.
Our results showed that in the primary site epitheiliod melanoma cells (E:WM-115) both cyclins E and A are overexpressed. We believe the observed cyclin E overexpression Helical models for each peptide were generated using the Maestro interface for MacroModel and subjected to a small 500-step conjugate gradient minimization using the OPLS-AA forcefield (27) with continuum solvent (28) . Side View of the Key Leucine and the RYG (argine, tyrosine, glycine residues, respectively) possibly involved in DNA contacts. (B) Top view of GIPs, looking down the axis of the helix, highlighting the differences in sequence among the three GIPs. Note: the tri-peptide that contains each GIP unique dipeptide residues which are adjacent to the key leucine residue (AA118,119 and 120 for H-TIG3 111-123 and Ha-Rev107 111-123 ; AA166, 167 and 168 for LRAT 160-171:C168L ).
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combined with its ectopic distribution of cyclin E can in part account for the hyper-proliferative nature of this tumor cell type ( Figure 4C.2) . This is reasonable since it has been shown that cytoplasmic cyclin E is capable of cdk2-independent S-phase entry (42) and that overexpression of cyclin E can result in accelerated S phase entry (43) .
Since the GIPs were not capable of significant downregulation of the overexpressed cyclins E and A, the observed GIPinduced abrogation of their cognate kinase, cdk2 ( Figure 4B ), is not only advantageous but likely the key to the observed reduced proliferation (Figure 2A) . Importantly, this level of regulation may have relevance because there is evidence that proliferation rates in human malignant melanoma is linked to clinical outcome (44) , and the literature is replete with evidence for the role of cdk2 in delaying the S-phase.
Thus we suggest that the GIPs target multiple transcription factors involved in cell cycle regulation ( Figure 9 ). The most significant consequence of this targeting is likely failed complex formation of cdk2 with cyclin E, which would result in a lower level of cdk2/cyclin E complex than is needed for triggering S-phase entry (19, 43) . Indeed, we found that GIPtreated primary site melanoma cells exhibited slowed growth without evidence of morphological differentiation or cell death by trypan blue staining and light microscopy (data not shown).
Additionally, GIPs could affect an S phase arrest ( Figure 9 ) in these peptide-sensitive melanoma cells. Failure of cyclin Acdk2 complex formation would prevent late G1!S transit thus interrupting mitosis; further failure by cdk2 phosphorylation of E2F would prevent formation of pre-initiation complexes and result in growth arrest (19) . However, we note that growth arrest did not occur in vitro and that the in vivo tumors in which the size of the tumor remained the same with GIP treatment might reflect growth arrest. Yet, this growth arrest was released within 7 days. We suggest that irreversible growth arrest did not occur because the GIPs, though capable of pushing transformed cells toward normal homeostasis, are not sufficient to resolve the pathology, which possibly requires cell death. It might be relevant that we observed that transient overexpression of RAR-b in E:WM-115 melanoma cells resulted in frank apoptosis within 48 h. This was enhanced by the exposure of the transfected melanoma cells to 9 cis-retinoic acid, the RAR-RXR ligand (45) (Figure 10 ). Further, this observation minimally suggests that the GIPs can identify useful molecular targets, for example RAR-b ( Figures 4A and 7) .
Interestingly, our results indicate that while H-TIG-3 1-164 , H-Ha-Rev107-1 , and H-LRAT 1-230 share this 12-amino LRAT-like proteins possesses anti-proliferative activity acid sequence homology and a degree of structural homology within the homologous sequence (Figure 8 ), biological activity (as cell growth inhibitors) is common only to wild-type peptides from the full-length tumor suppressor proteins and not wild-type LRAT 160-171 peptide. However, a single amino acid substitution (Figure 1 ) obtained the desired result (Figure 2A) . Moreover, as discussed in the Molecular modeling Section, while we do not yet fully understand the significance of the leucine residue, we do observe that the unique tri-peptide sequences with growth inhibitory activity have a leucine in Position 3 as does the tri-peptide sequence NYL found in the M4 region of DNA-binding zinc fingers and that the GIP with tri-peptides which have two residues in common with the zinc-finger NYL tri-peptide possess higher growth inhibitory activity. Thus we note that H-TIG3 111-123 (NEL) 4 H-LRAT 160-171:C168L (TYL) 4 H-Rev107 111-123 (AQL) 4 H-LRAT 160-171 (TYC) ¼ H-TIG3 111-123:L120C (NEC). In terms of single amino acid substitutions and LRAT activity/ function, it has been reported that single amino acid substitutions at Position C168 in H-LRAT are to a lesser extent important for LRAT catalysis than C161 mutations and that C168 could be important for structure maintenance or a second transfer reaction not absolutely essential to catalysis (7) . Indeed, we have suggested that perhaps mutations at this position have as a consequence additional functions of the LRAT protein, e.g. growth inhibitory (16) . Insofar as the significance of the leucine at this position in both the mutated LRAT peptide as well as the wild-type peptides from the full-length tumor suppressor proteins is unknown, we suggest that our work is the first to implicate this leucine residue as important in peptide-DNA binding kinetics and ostensibly the full-length proteins. It is interesting to speculate that AQ, NE, TY in the unique tri-peptides might affect affinity/avidity of binding ( Figure 8B) . A more complete understanding might be had by the study of binding kinetics of the peptides/full-length proteins with DNA. In light of our observations and recent studies that report another isoform of H-Ha-Rev107 tumor suppressor with acyltransferase properties (8, 41) , it is interesting to consider that there may exist isoforms of the LRAT enzyme that possess tumor suppressor properties.
In support of our peptide-DNA binding observations (Figure 7 ), a search in VAST generated several structures that possess partial structural homology to truncated H-LRAT (truncated LRAT). Among these structures is 1BRN, a short segment of DNA complexed with RNase/ endonuclease. Indeed, 1BRN barnase interacts with the phosphates of the DNA (47) , an interaction we hypothesize occurs through the common tri-peptide RYG in the growth inhibitory peptides. As noted earlier this shared tri-peptide may have relevance in the observed peptide-DNA binding since these residues are also found in RARs and are shown to interact with the phosphate backbone of DNA. We also note that this truncated form of LRAT includes the sequence homologous region and find it interesting that the truncated LRAT is also used to study LRAT enzyme function/activity.
We would like to propose that the sequence homologous peptides mimic behavior of their respective regions within the full-length proteins as suggested by our model (Figure 9 ). This is a reasonable consideration because our molecular modeling, in which multiple secondary-structure prediction algorithms were applied, suggests an alpha-helix formation of these regions in their respective full-length proteins (data not shown) as well as for the sequence homologous peptides ( Figure 8A ). Additionally, Duecher et al. (46) demonstrated full-length TIG-3 1-164 having peri-nuclear localization and suppressing colony formation 50-70%, while our data show that the sequence homologous peptides, e.g. TIG [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] , can localize to the nucleus and inhibit cell proliferation (Figures 1,  3 and 5) .
Thus the fact that we find the GIPs localized to the nucleus not only suggests the peptides' behavior can lend insight into the behavior of their full-length proteins, but it also implicates DNA interaction as a functional aspect of these proteins. Of course, these observations and conclusions do not preclude the possibility that these full-length proteins can have additional functions in the cytoplasm and nucleus. However, this is the first study to demonstrate DNA interaction of peptides from these LRAT-like proteins.
